Structure Database (LMSD)
LMSD: Structure-based search results
LM_ID | Common Name | Systematic Name | Formula | Mass | Main Class | Sub Class |
---|---|---|---|---|---|---|
LMFA04010008 | 4-F4-NeuroP | (E)-6-(3,5-dihydroxy-2-((2Z,5Z,8Z)- undeca-2,5,8-trien-1-yl)cyclopentyl)-4- hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010011 | ent-4-F4t-NeuroP | (R,E)-6-((1R,2S,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010012 | ent-7-epi-4-F4c-NeuroP | (R,E)-6-((1R,2R,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010013 | ent-7-epi-4-F4t-NeuroP | (R,E)-6-((1S,2S,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010014 | ent-4-F4c-NeuroP | (R,E)-6-((1S,2R,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010015 | 4-epi-4-F4c-NeuroP | (R,E)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010016 | 4,7-diepi-4-F4t-NeuroP | (R,E)-6-((1R,2R,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010017 | 4,7-diepi-4-F4c-NeuroP | (R,E)-6-((1S,2S,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010018 | 4-epi-4-F4t-NeuroP | (R,E)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010019 | ent-4-epi-4-Ft-NeuroP | (S,E)-6-((1R,2S,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010020 | ent-4,7-diepi-4-Fc-NeuroP | (S,E)-6-((1R,2R,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010021 | ent-4,7-diepi-4-Ft-NeuroP | (S,E)-6-((1S,2S,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010022 | ent-4-epi-4-Fc-NeuroP | (S,E)-6-((1S,2R,3S,5R)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010023 | 4-F4c-NeuroP | (S,E)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010024 | 7-epi-4-F4t-NeuroP | (S,E)-6-((1R,2R,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010025 | 7-epi-4-F4c-NeuroP | (S,E)-6-((1S,2S,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |
LMFA04010026 | 4-F4t-NeuroP | (S,E)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2- ((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl) cyclopentyl)-4-hydroxyhex-5-enoic acid | C22H34O5 | 378.2406 | Docosanoids [FA04] | Neuroprostanes [FA0401] |